Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

NanoViricides Starts Drug Development Program For Recent Cases Of Unexplained Pediatric Hepatitis

Published 16/05/2022, 17:22
Updated 16/05/2022, 18:10
© Reuters.  NanoViricides Starts Drug Development Program For Recent Cases Of Unexplained Pediatric Hepatitis

© Reuters. NanoViricides Starts Drug Development Program For Recent Cases Of Unexplained Pediatric Hepatitis

  • NanoViricides Inc (NYSE: NNVC) has initiated a program to screen its library of broad-spectrum antiviral nanoviricides against human Adenovirus 41 Type F (hAd41-F), believed to be strongly associated with the occurrence of severe hepatitis syndrome in some children.
  • The company says its top priority remains to initiate human trials of its SARS-CoV-2 drug candidate NV-CoV-2 to combat COVID-19.
  • NanoViricides expects filing a clinical trial application for COVID-19 to occur relatively soon, although the timelines are outside the company's control.
  • Related: EXCLUSIVE: NanoViricides Develops Chewable Pills, Lung Inhalation Formulations For COVID-19 Candidate.
  • The company believes it can successfully develop a drug candidate against hAd41-F relatively quickly if one or more of its existing pipeline candidates or other nanoviricide candidates in its drug candidate library is effective.
  • NanoViricides is developing an antiviral assay for testing these drug candidates against hAd41-F infection in cell cultures in its virology facility.
  • It is thought that a combination of prior SARS-CoV-2 exposure or infection, along with current hAd41-F infection, may be responsible for hepatitis cases. However, no definitive cause of this severe hepatitis syndrome has been established.
  • As reported by NBC News online, the number of cases worldwide has risen to 450 as of May 15.
  • Related: Six US States Probing Mysterious Liver Inflammation In Kids: Bloomberg.
  • Price Action: NNVC shares are up 16.10% at $1.50 during the market session on the last check Monday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.